Evidence map›Paper›PMID 26675261›Full record

ArticleOncotarget2016

Mps1 is SUMO-modified during the cell cycle.

Agnese Restuccia, Feikun Yang, Changyan Chen, Lou Lu, Wei Dai

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Mps1 is associated with the BRAFOncology letters · 2019
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Agnese RestucciaDivision of Virus-Associated Carcinogenesis, German Cancer Research Center, Heidelberg, Germany.
Feikun YangDepartments of Environmental Medicine, Biochemistry and Molecular Pharmacology, New York University Langone Medical Center, Tuxedo Park, NY, USA.
Changyan ChenCenter for Drug Discovery, Northeastern University, Boston, MA, USA.
Lou LuDivision of Molecular Medicine, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Torrance, CA, USA.
Wei DaiDepartments of Environmental Medicine, Biochemistry and Molecular Pharmacology, New York University Langone Medical Center, Tuxedo Park, NY, USA.
NYU Langone Health · USHeidelberg University · DENortheastern University · USUniversity of California, Los Angeles · US

Funding

RESEARCH IN ENVIRONMENTAL HEALTH SCIENCES (CENTER GRANT)P30ES000260 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZELIKOFF, JUDITH TERRY · 1985 to 2020
$26.1M
Ex Vivo Expansion of Human Limbal Stem Cells for TransplantationR01EY021797 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Sophie Deng · 2012 to 2026
$5.1M
Role of CTCF in EGF_Induced Corneal Epithelial GrowthR01EY015281 · NEI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI LU, LUO · 2004 to 2014
$3.0M
Molecular mechanisms underlying chromosomal instability and aneuploidyR01CA090658 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DAI, WEI · 2001 to 2012
$2.9M
Study of Ras-Mediated ApoptosisR01CA100498 · NCI · NORTHEASTERN UNIVERSITY · PI CHEN, CHANGYAN · 2004 to 2017
$2.5M
Plk3, A New Player In The Hypoxia Regulatory Networ.R01CA150512 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DAI, WEI · 2011 to 2015
$1.6M
Study of Anti-Survival signals in NF1R01CA153354 · NCI · NORTHEASTERN UNIVERSITY · PI CHEN, CHANGYAN · 2012 to 2017
$1.6M
Differential Effects of Corneal Hypoxia on Limbal Stem and Epithelial Cell FatesR01EY022364 · NEI · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI LU, LUO · 2012 to 2016
$1.6M
NCI NIH HHS CA090658NCI NIH HHS CA100498NCI NIH HHS CA150512NCI NIH HHS CA153354NCI NIH HHS R01 CA090658NCI NIH HHS R01 CA100498NCI NIH HHS R01 CA150512NCI NIH HHS R01 CA153354NEI NIH HHS EY021797NEI NIH HHS R01 EY015281NEI NIH HHS R01 EY021797NEI NIH HHS R01 EY022364NIEHS NIH HHS ES000260NIEHS NIH HHS P30 ES000260
6 · The paper itself

Abstract

Mps1 is a dual specificity protein kinase that regulates the spindle assembly checkpoint and mediates proper microtubule attachment to chromosomes during mitosis. However, the molecular mechanism that controls Mps1 protein level and its activity during the cell cycle remains unclear. Given that sumoylation plays an important role in mitotic progression, we investigated whether Mps1 was SUMO-modified and whether sumoylation affects its activity in mitosis. Our results showed that Mps1 was sumoylated in both asynchronized and mitotic cell populations. Mps1 was modified by both SUMO-1 and SUMO-2. Our further studies revealed that lysine residues including K71, K287, K367 and K471 were essential for Mps1 sumoylation. Sumoylation appeared to play a role in mediating kinetochore localization of Mps1, thus affecting normal mitotic progression. Furthermore, SUMO-resistant mutants of Mps1 interacted with BubR1 more efficiently than it did with the wild-type control. Combined, our results indicate that Mps1 is SUMO-modified that plays an essential role in regulating Mps1 functions during mitosis.

Indexed as

Cell Cycle ProteinsCell Line, TumorHEK293 CellsHeLa CellsHumansKinetochoresMitosisProtein Serine-Threonine KinasesProtein-Tyrosine KinasesRNA InterferenceRNA, Small InterferingSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinSumoylationBUB1 protein, humanCell Cycle ProteinsProtein Serine-Threonine KinasesProtein-Tyrosine KinasesRNA, Small InterferingSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinSUMO2 protein, humanTTK protein, humanBubR1mitosisMps1sumoylation

Identifiers

PMID26675261
PMCPMC4823097
OpenAlexW2219764357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.